https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an international breast cancer study group report https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21434 15% was seen in patients aged <40 years (16.1%), with ≥4 positive nodes (16.5%) or 0–7 uninvolved nodes (15.1%); for supraclavicular failures >10%: ≥4 positive nodes (10.2%); for axillary failures of >5%: aged <40 years (5.1%), unknown primary tumor size (5.2%), 0–7 uninvolved nodes (5.2%). In patients with 1–3 positive nodes, 10-year cumulative incidence for chest wall recurrence of >15% were age <40, peritumoral vessel invasion or 0–7 uninvolved nodes. Age, number of positive nodes and number of uninvolved nodes were significant parameters for each locoregional relapse site. Conclusion: PMRT to the chest wall and supraclavicular fossa is supported in patients with ≥4 positive nodes. With 1–3 positive nodes, chest wall PMRT may be considered in patients aged <40 years, with 0–7 uninvolved nodes or with vascular invasion. The findings do not support PMRT to the dissected axilla.]]> Sat 24 Mar 2018 08:05:46 AEDT ]]> Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5363 Sat 24 Mar 2018 07:43:57 AEDT ]]>